BAXDELA

Drug Melinta Therapeutics, Inc.
Total Payments
$42,809
Transactions
8
Doctors
5
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2019 $42,809 8 5

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $42,752 1 99.9%
Food and Beverage $56.70 7 0.1%

Payments by Type

Research
$42,752
1 transactions
General
$56.70
7 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
306DH Melinta Therapeutics, Inc. $42,752 0

Top Doctors Receiving Payments for BAXDELA

Doctor Specialty Location Total Records
Unknown Atlanta, GA $42,752 1
, M.D Infectious Disease Saint Petersburg, FL $21.75 1
, DPM Podiatrist Gastonia, NC $12.37 1
, D.P.M Podiatrist Independence, MO $11.37 2
, MD Emergency Medicine Kansas City, KS $10.61 2
, DO Family Medicine Kirksville, MO $0.60 1

About BAXDELA

BAXDELA is a drug associated with $42,809 in payments to 5 healthcare providers, recorded across 8 transactions in the CMS Open Payments database. The primary manufacturer is Melinta Therapeutics, Inc..

Payment data is available from 2019 to 2019. In 2019, $42,809 was paid across 8 transactions to 5 doctors.

The most common payment nature for BAXDELA is "Unspecified" ($42,752, 99.9% of total).

BAXDELA is associated with 1 research study, including "306DH" ($42,752).